SMMT – summit therapeutics inc. (US:NASDAQ)
Stock Stats
News
1/14
10:00 am
smmt
Medium
Summit Therapeutics (NASDAQ:SMMT) was given a new $40.00 price target on by analysts at Piper Sandler.
1/14
08:42 am
smmt
Medium
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/13
01:36 pm
smmt
Low
Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge [Yahoo! Finance]
1/13
12:37 am
smmt
Low
Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? [Yahoo! Finance]
1/12
12:16 pm
smmt
Low
2 Biotech Stocks That Could Soar This Year [Yahoo! Finance]
10/20/2025
06:45 am
smmt
-4.3%
BEAT
8/11/2025
05:03 pm
smmt
-3.2%
MISS
5/1/2025
04:09 pm
smmt
12.3%
BEAT
2/24/2025
06:05 am
smmt
-20.3%
BEAT
1/14
08:42 am
Reiterates
Buy
Buy
HC Wainwright
Medium
5.0%
12/17
09:44 am
Upgrades
Underweight
Equal-Weight
Barclays
Medium
-3.4%
12/17
09:44 am
Upgrades
Underweight
Equal-Weight
Barclays
Medium
-3.4%
12/17
09:12 am
Upgrades
Underweight
Equal Weight
Barclays PLC
Low
-2.3%
12/17
05:40 am
Upgrades
UNDERWEIGHT
EQUAL WEIGHT
BARCLAYS
Low
-2.7%
1/12
04:02 pm
smmt
Low
Form 4 Summit Therapeutics Inc. For: Jan 08 Filed by: Anand Bhaskar
1/12
07:43 am
smmt
High
Form 8-K Summit Therapeutics Inc. For: Jan 12
1/6
07:53 pm
smmt
Low
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Zanganeh Mahkam
1/6
07:50 pm
smmt
Low
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: DUGGAN ROBERT W
1/6
06:55 pm
smmt
Low
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Booth Robert F.
Show more
Top News Gainers
4/14 Summit Appoints Robert W. Duggan as Chief Executive Officer 27.7%
3/13 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 22.3%
6/15 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating. 13.3%
12/6 Form 6-K Summit Therapeutics plc For: Dec 06 10.8%
12/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
7/9 Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia 8.2%
3/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 7.8%
10/3 Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care 6.1%
2/4 Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference 4.0%
12/6 Form 6-K/A Summit Therapeutics plc For: Dec 06 3.9%
Top News Decliners
5/1 SUMMIT THERAPEU/S (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock. -12.0%
10/1 Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 -10.7%
12/17 Form 6-K Summit Therapeutics plc For: Oct 31 -5.8%
10/11 Half-year report -5.7%
10/3 Summit Therapeutics up 17% premarket on positive ridinilazole data in CDI patients [Seeking Alpha] -5.5%
5/14 Form 6-K Summit Therapeutics plc For: May 14 -4.8%
11/8 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -4.6%
1/27 Form 6-K Summit Therapeutics plc For: Jan 27 -3.9%
4/30 Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress -3.8%
7/17 Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress -3.8%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3